NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are sold for the same purpose: to raise NAD+, the coenzyme described on our NAD+ vs NMN page. They are close relatives: NMN is NR with a phosphate group attached.
The usual comparison online argues from that chemistry. This page starts from the one published randomised trial that gave both to people, then sets the two records side by side. It reports what was measured; it does not say which to take. How NMN compares with NAD+ itself is on that page, and the side-effect record for every oral precursor is on our NAD side effects page.
The two molecules
| NMN | NR | |
|---|---|---|
| Full name | Nicotinamide mononucleotide | Nicotinamide riboside (sold as the chloride salt) |
| Formula / molecular weight | C11H15N2O8P / 334.2 | C11H15ClN2O5 / 290.7 (chloride salt) |
| Relationship | NR plus one phosphate group | NMN minus its phosphate group |
| Molecules in 1 gram | 3.0 millimoles | 3.4 millimoles |
The last row matters for any comparison made in grams. A gram of NR contains roughly 13% to 15% more molecules than a gram of NMN (3.4 against 3.0 millimoles as the head-to-head trial states them; 334.2 ÷ 290.7 from the molecular weights).
The one randomised head-to-head trial
Christen et al., Nature Metabolism, January 2026 (PMID 41540253; NCT05517122; full text read for this page).
| Who ran it | Nestlé Research, Lausanne; eleven of the twelve authors are employees of Nestlé companies (the paper's own disclosure) |
|---|---|
| When | 14 July to 24 November 2022 |
| Design | Randomised, placebo-controlled, four arms, open label |
| People | 67 enrolled, 65 analysed; mean age 34.7; 32 men and 33 women; lean (mean BMI 21.4 in women, 23.7 in men) |
| Arms | NR 1 g a day (17 people), NMN 1 g a day (15), nicotinamide 0.5 g a day (17), placebo (18), once daily for 14 days |
| Products | A commercial NR capsule and a commercial NMN capsule, named in the methods |
| Primary outcome | Change in baseline whole-blood NAD+ after 14 days |
What it found.
| Arm | Rise in whole-blood NAD+ over placebo at day 14 | 95% confidence interval | Per millimole swallowed (our arithmetic) |
|---|---|---|---|
| NR, 1 g a day | 49.4 micromolar | 39.5 to 59.3 | 14.5 |
| NMN, 1 g a day | 43.1 micromolar | 32.7 to 53.4 | 14.4 |
| Nicotinamide, 0.5 g a day | No significant rise (P = 0.461) | — | — |
The paper describes both rises as roughly a doubling and as comparable. The two confidence intervals overlap for most of their length. Dividing each rise by the millimoles given removes what is left of the gap: 49.4 ÷ 3.4 is 14.5 and 43.1 ÷ 3.0 is 14.4. On this trial's numbers, molecule for molecule, the two rises were almost identical. The authors' own wording is that the two "are comparable in their ability to chronically increase baseline whole-blood NAD+ levels".
Side effects. Three adverse events were judged probably related to a product among the 65 people: abdominal pain in one person on placebo, low blood pressure in one on NR, and headache in one on NMN.
The part that complicates both products' marketing. In the four hours after a dose, the abstract reports that only nicotinamide changed the blood's NAD+-related metabolites, and only briefly; the rise from NMN and NR showed up over the 14 days, not after a single dose. The authors then put each compound in contact with human gut bacteria in the laboratory. The bacteria converted NR and NMN to nicotinic acid, and in separate tests on human blood, nicotinic acid raised NAD+ strongly while NMN, NR and nicotinamide did not. Their proposed model is that much of the effect of both supplements runs through gut bacteria and nicotinic acid, the form of vitamin B3 known as niacin. The paper calls this a proposal.
What the trial cannot show. It was open label. It ran 14 days in young, lean, healthy adults, and the authors note that NAD+ was pushed above normal values, not restored from a deficit. It measured blood, not muscle, brain or any symptom. And it has not been repeated in a second randomised trial with results (next section).
Other studies that involve both
A ClinicalTrials.gov search on 13 November 2026 for studies naming both compounds as interventions returned three records besides the Nestlé trial. None has posted results.
| Registry record | Sponsor | Design | Status on 13 November 2026 |
|---|---|---|---|
| NCT05698771, "NAD-brain" | Haukeland University Hospital, Norway | Not randomised, 12 people; in its first stage six healthy people received NR and six received NMN, each 1,200 mg a day for 8 days | Completed 4 March 2024; no results posted; a PubMed search for the registry number returned nothing |
| NCT06991712 | Christopher Kai Shun Leung (Hong Kong) | Randomised and masked, about 138 people with glaucoma; NR and nicotinamide in one phase, NMN and nicotinic acid in another, each against placebo | Recruiting |
| NCT06627868 | University of Turku, Finland | Randomised, about 68 people; an "oral NAD+ precursor" against placebo, not a comparison of the two | Recruiting |
A PubMed search the same day for clinical-trial records mentioning both compounds returned five, of which only the Nestlé trial randomised people to one or the other.
The records behind each, counted
Counts taken on 13 November 2026. Each search was first run on semaglutide as a check that the filter returns results (112 registry studies with results; 270 randomised-trial records).
| NMN | NR | |
|---|---|---|
| ClinicalTrials.gov studies naming it as an intervention | 33 | 126 |
| Of those, completed | 14 | 56 |
| Of those, with results posted on the registry | 1 | 17 |
| PubMed records indexed as randomised controlled trials with the name in the title | 13 | 24 |
| Largest randomised trial read for this site | 108 older adults, 12 weeks (Kim, Nutrients 2022) | 410 people with early Parkinson's disease, 52 weeks (NOPARK, JAMA 2026) |
NR's registry record is about four times the size of NMN's, and the gap in posted results is wider: 17 against 1. A registry entry is a plan, not a finding, so the counts measure how much has been attempted, not what was shown.
What the larger trials of each measured
NR. Two trials stand out, and they point in different directions.
- NOPARK gave 410 people with recently diagnosed Parkinson's disease 1,000 mg a day or placebo for a year. Scores on the standard rating scale were 2.72 points worse on NR than on placebo, and the authors concluded the result does not support NR as a disease-modifying treatment. Serious adverse events were less frequent on NR (8.3% against 14.1%). The figures and their limits are on our NAD side effects page.
- NICE randomised 90 people with peripheral artery disease to NR, NR plus resveratrol, or placebo for six months (McDermott et al., Nature Communications 2024). Six-minute walking distance changed by +7.0 metres on NR and −10.6 on placebo, a difference of 17.6 metres (90% confidence interval from +1.8 metres upward; a one-sided test). The authors wrote that a larger trial is needed to confirm it. The paper carries a published erratum; the abstract was read for this page, not the full text.
NMN. The eleven randomised trials with a stated oral dose are tabled one row each on our NAD+ vs NMN page and are not repeated here. In summary: 14 to 108 people, 2 to 24 weeks, blood NAD+ or its metabolites up where measured, functional results mixed, and ten of the eleven with a company author or company funding. Women-only evidence, a single 25-person trial, is on NAD for women.
Neither compound has a trial showing it prevents or treats a disease. NR's largest trial went against it; its best functional result awaits confirmation. NMN has no trial of comparable size or length in either direction.
Regulatory standing in the US
| NMN | NR | |
|---|---|---|
| FDA food-safety (GRAS) notice | Not established by this page: the notice list's search could not be read automatically on 13 November 2026 | NR chloride: GRN 635, notifier ChromaDex, filed 29 March 2016, closed 3 August 2016, "FDA has no questions" |
| What that notice covers | — | Use as a source of vitamin B3 in foods such as vitamin waters, protein shakes and nutrition bars, at up to 0.0057% by weight |
| Supplement status | FDA stated in 2022 that NMN was excluded from the supplement definition; a response letter posted 29 September 2025 reversed that | Not subject to that dispute |
| Approved as a drug for anything | No | No |
"FDA has no questions" is the agency's standard closing response to a notice. It is not an approval, and it concerns the food uses in the notice, not a 1,000 mg capsule or any health claim. The NMN reversal, and the limits of what this site could read of FDA's letter, are documented on our NAD+ vs NMN page.
What is not established
- Whether either raises NAD+ in muscle, brain or other tissue to a degree that changes anything a person would notice. The head-to-head trial measured blood.
- Whether the two differ on any clinical outcome. No completed trial has compared them on one; a glaucoma trial that includes both is recruiting.
- Whether the gut-bacteria route the Nestlé group proposes is the main route in people. One group has reported it.
- Long-term safety of NMN: its longest trials ran 24 weeks in 14 men. NR has one year in 410 people with Parkinson's disease, a population that does not stand in for healthy users.
- Whether a given capsule contains what its label states. Supplements are not tested by FDA before sale.
Anyone weighing either for a medical reason, or alongside prescription medicines, should take the specific product and this record to a doctor. Injected and infused NAD+ are a separate question with a separate record: see NAD+ injection vs oral.
Sources and dates
- Christen S et al. Nat Metab 2026;8(1):62-73. PMID 41540253; full text PMC12855009 read 13 November 2026 (design, arm sizes, doses in grams and millimoles, NAD+ differences and confidence intervals, adverse events, limitations). Registry record NCT05517122 read the same day (sponsor Société des Produits Nestlé; completed 24 November 2022; the registry lists 68 enrolled, the paper reports 67).
- McDermott MM et al. Nat Commun 2024;15(1):5046. PMID 38871717. Abstract read 13 November 2026.
- ClinicalTrials.gov API v2, intervention queries for "nicotinamide riboside" and "nicotinamide mononucleotide", all studies, completed, and with results, and for both names together (4 records: NCT05517122, NCT05698771, NCT06991712, NCT06627868); read 13 November 2026.
- PubMed, "nicotinamide riboside"[Title] and "nicotinamide mononucleotide"[Title], each limited to randomised controlled trials; both names in title or abstract, limited to clinical trials (5 records: PMIDs 41540253, 37271226, 35182418, 32758058, 29211728, titles read); registry number NCT05698771 (0 records). Read 13 November 2026.
- FDA GRAS Notice Inventory, GRN No. 635 (nicotinamide riboside chloride), read 13 November 2026.
- PubChem, nicotinamide riboside chloride (CID 90480033), molecular formula and weight, read 13 November 2026; NMN as on our NAD+ vs NMN page.
- NOPARK, the NMN trial table and the FDA response letter of 29 September 2025: as read and dated on our NAD side effects and NAD+ vs NMN pages.
